(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 December 2012 (20.12.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/173808 A1

(51) International Patent Classification:
A61K 31/7004 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/US2012/040789

(22) International Filing Date:
4 June 2012 (04.06.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/520,031	3 June 2011 (03.06.2011)	US
61/541,333	30 September 2011 (30.09.2011)	US
61/618,680	31 March 2012 (31.03.2012)	US

(71) Applicant *(for all designated States except US)*: **ELAN PHARMACEUTICALS, INC.** [US/US]; 180 Oyster Point Blvd., South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ABUSHAKRA, Susan** [US/US]; 180 Oyster Point Blvd. (US). **CRANS, Gerald** [US/US]; 180 Oyster Point Blvd. (US). **CEDARBAUM, Jesse** [US/US]; 180 Oyster Point Blvd. (US). **HERNANDEZ, Ramon** [US/US]; 180 Oyster Point Blvd. (US).

(74) Agent: **EVANS, David, W.**; Elan Pharmaceuticals, Inc., 180 Oyster Point Blvd., South San Francisco, CA 94080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2012/173808 A1

(54) Title: SCYLLO-INOSITOL FOR THE TREATMENT OF BEHAVIORAL AND PSYCHIATRIC DISORDERS

(57) Abstract: The invention relates to the treatment of disorders associated with elevated myo-inositol levels in brain, in particular behavioural and neuropsychiatry disorders such as dementia, mild Alzheimer's disease, mild cognitive impairment or bipolar disorder by administering an effective amount of scyllo-inositol to a subject.